title: Transurethral injection of bulking agent for treatment of failed mid-urethral sling procedures.
abstract: OBJECTIVE
  We evaluated the efficacy of transurethral injection (TUI) for the treatment of recurrent or persistent stress urinary incontinence after mid-urethral sling (MUS) procedures.
  
  
  METHODS
  A retrospective study was conducted among 23 women who had undergone TUI for failed MUS using bulking agents, Macroplastique® and Durasphere®. The Sandvik questionnaire, Subjective Symptom Visual Analogue Scale (VAS), Incontinence Quality of Life (I-QOL) assessment, and Benefit, Satisfaction, and Willingness to Continue questionnaire were used to evaluate the efficacy of TUI.
  
  
  RESULTS
  The cure rate was 34.8% for a median follow-up of 10 months. Subjective symptom VAS, total, and all domains of I-QOL scores were significantly improved after TUI. Ninety-two percent of the patients reported a benefit and 77% of the patients were satisfied with the treatment.
  
  
  CONCLUSIONS
  TUI for failed MUS demonstrated a low cure rate but high patient satisfaction, and the procedure was minimally invasive with no significant complications.
authors.affiliation: Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
authors.forename: Ha Na
authors.initials: HN
authors.lastname: Lee
authors.forename: Young-Suk
authors.initials: YS
authors.lastname: Lee
authors.forename: Ji-Yeon
authors.initials: JY
authors.lastname: Han
authors.forename: Jae Yong
authors.initials: JY
authors.lastname: Jeong
authors.forename: Myung-Soo
authors.initials: MS
authors.lastname: Choo
authors.forename: Kyu-Sung
authors.initials: KS
authors.lastname: Lee
mesh_terms: D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D004129:Dimethylpolysiloxanes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004868:Equipment Failure; D005260:Female; D005500:Follow-Up Studies; D005936:Glucans / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007267:Injections; D008875:Middle Aged; D017060:Patient Satisfaction; D012189:Retrospective Studies; D053825:Suburethral Slings; D016896:Treatment Outcome; D014550:Urinary Incontinence, Stress / Q000628:therapy*; D015040:Zirconium / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D004129:Dimethylpolysiloxanes; D005936:Glucans; C431745:durasphere; C013830:baysilon; D015040:Zirconium